Key result
Review outlines current post-ablation management strategies for VT including AADs and ICDs.
Why the study?
The management of patients after catheter ablation of ventricular tachycardia is not well defined.
What is the optimal management strategy for patients after catheter ablation of ventricular tachycardia?
What is the optimal management strategy for patients after catheter ablation of ventricular tachycardia?
This review summarizes current evidence and clinical experience regarding the management of patients following ventricular tachycardia ablation, including risk stratification and concomitant therapies like ICDs and antiarrhythmic drugs.
Management after ventricular tachycardia ablation remains guided by limited evidence; leaves open the need for randomized trials on antiarrhythmic drugs and ICDs.
The management of patients after catheter ablation of ventricular tachycardia is not well defined. In this article we summarize recently published results and report our own experience. Factors influencing the clinical outcome of these patients and methods to identify patients with an increased risk of recurrence of ventricular tachycardia are discussed. Furthermore, a review is given on current concomitant therapeutic tools including antiarrhythmic drugs and the implantation of an automatic cardioverter defibrillator.
No takes yet. Share an insight, caveat, or question.
GONSKA et al. (1994) conducted a review in Ventricular tachycardia after catheter ablation. Management strategies (antiarrhythmic drugs, ICD) was evaluated. This review summarizes current management strategies, including antiarrhythmic drugs and ICD implantation, for patients after catheter ablation of ventricular tachycardia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: